Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Coverage varies by plan type
Clinical and experimental studies reveal altered gut microbial diversity and metabolite profilessuch as elevated trimethylamine N-oxide and reduced short-chain fatty acidshighlighting the gut microbiota as a promising therapeutic target in stroke prevention and treatment (Peh et al., 2022)
An intrinsic agonist mechanism for activation of glucagon-like peptide-1 receptor by its extracellular domain
KEY FEATURES CJC-1295 NO DAC + IPA lyophilised research-grade peptide 5mg/5mg per vial Independent HPLC-MS verified to 99.00% purity (CoA on public Lab Results portal) Single-batch fill, single-batch chromatogram no blending across lots Synthesised in accredited contract laboratories with full QA paper trail Crimp-sealed, tamper-evident research vial in unbranded outer packaging Dispatched from Australia on Auspost Express with insulated cold-pack option SPECIFICATIONS Product Name CJC-1295 NO DAC + IPA Category Proprietary Research Blends Grade Research grade laboratory use only Quantity 5mg/5mg per vial Form Lyophilised powder cake Purity 99.00% verified by HPLC-MS Appearance White to off-white lyophilised solid Storage 28 C lyophilised
